

---

**ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN  
PHARMACEUTICAL FORMULATIONS**

---

**Anjali Ghanshala\* Aryan Rakhwal, Ashish Yadav, Nisha Gupta, Vikas Chauhan, Nakul  
Gupta**

---

IIMT College of Pharmacy, A.P.J Abdul Kalam Technical University (AKTU), Knowledge  
Park 3, Greater Noida. Gautam Budha Nagar – 201310, U.P, India.

---

**Article Received: 22 March 2026**

**Article Revised: 12 April 2026**

**Published on: 02 May 2026**

**\*Corresponding Author: Anjali Ghanshala**

IIMT College of Pharmacy, A.P.J Abdul Kalam Technical University (AKTU),  
Knowledge Park 3, Greater Noida. Gautam Budha Nagar – 201310, U.P, India.

DOI: <https://doi-doi.org/101555/ijrpa.7958>

---

**ABSTRACT**

Artificial Intelligence (AI) and Machine Learning (ML) are rapidly transforming the pharmaceutical industry, particularly in the field of pharmaceutical formulations. Traditional formulation development is often expensive, time-consuming, and dependent on repeated trial-and-error experimentation. Scientists must optimize numerous variables such as excipient selection, drug release profile, stability, manufacturing parameters, and patient acceptability before achieving a successful product. AI and ML provide a powerful data-driven alternative by analysing large datasets, identifying hidden relationships, and predicting outcomes with high precision. These technologies can significantly reduce development timelines, lower costs, improve product quality, and accelerate innovation.

In pharmaceutical formulations, AI models are increasingly used in preformulation studies to predict solubility, stability, polymorphism, hygroscopicity, and compatibility between drug substances and excipients. During product development, ML algorithms can optimize concentrations of binders, disintegrants, lubricants, polymers, and coating materials while minimizing the number of laboratory experiments required. Neural networks, support vector machines, random forest models, and deep learning approaches have demonstrated strong predictive performance for tablet hardness, friability, dissolution, bioavailability, and shelf-life. AI also plays a vital role in manufacturing and quality assurance. By integrating with Process Analytical Technology (PAT), sensors, and real-time monitoring systems, AI enables continuous process verification, predictive maintenance, deviation detection, and autonomous process control. In quality control laboratories, computer vision systems can detect visual

defects in tablets, capsules, and packaging more efficiently than manual inspection.

Furthermore, AI supports personalized medicine by enabling patient-specific dosage forms, especially in conjunction with 3D printing technologies. Despite these advantages, challenges remain, including poor data quality, limited datasets, model interpretability, cybersecurity risks, lack of regulatory harmonization, and the need for trained professionals. Nevertheless, the future of pharmaceutical formulations will increasingly depend on intelligent systems integrated with robotics, digital twins, generative AI, and smart manufacturing platforms. This review highlights the major applications, benefits, limitations, and future opportunities of AI and ML in pharmaceutical formulations.

**KEYWORDS:** Artificial Intelligence, Machine Learning, Pharmaceutical Formulations, Drug Delivery, PAT, Personalized Medicine, Deep Learning

## INTRODUCTION

Pharmaceutical formulation is the science of converting an active pharmaceutical ingredient (API) into a safe, effective, stable, and patient-friendly dosage form. Common dosage forms include tablets, capsules, suspensions, emulsions, transdermal systems, injectables, inhalers, and novel drug delivery systems. The objective of formulation scientists is to ensure that the drug is delivered at the right dose, at the right rate, and at the right site of action while maintaining quality, stability, and manufacturability.

Traditionally, formulation development relies heavily on empirical methods and repeated experimentation. Scientists test multiple combinations of excipients and process variables such as granulation time, compression force, mixing speed, coating temperature, and drying conditions. This conventional approach often requires extensive resources and can delay product launch. In modern pharmaceutical markets, where competition is intense and patient needs are evolving rapidly, faster and more efficient development strategies are essential.

Artificial Intelligence (AI) refers to the ability of machines or computer systems to perform tasks that normally require human intelligence, such as learning, reasoning, prediction, optimization, and decision-making. Machine Learning (ML), a subset of AI, allows systems to learn patterns from data and improve performance without being explicitly programmed for every task. These technologies are now being widely adopted in healthcare, diagnostics, pharmacovigilance, supply chains, and pharmaceutical research. In pharmaceutical formulations, AI and ML can process complex datasets generated from experiments, historical batches, spectroscopy, imaging, dissolution studies, stability chambers, and manufacturing

systems. By recognizing relationships between input variables and product performance, AI can recommend optimized formulations, predict failures before they occur, and improve overall efficiency. Instead of relying solely on trial-and-error, formulation scientists can use predictive models to guide development decisions. The adoption of AI is closely aligned with Quality by Design (QbD), which emphasizes scientific understanding, risk management, and process control. AI strengthens QbD by providing robust predictive tools for defining design space, identifying critical material attributes (CMAs), and controlling critical process parameters (CPPs). Regulatory agencies are also encouraging digital transformation and advanced manufacturing technologies, creating new opportunities for intelligent pharmaceutical systems. This article discusses the major applications of AI and ML in pharmaceutical formulations, including preformulation studies, optimization, manufacturing, quality control, personalized medicine, challenges, and future trends.


## 1. Role of AI in Preformulation Studies


Preformulation is the first stage of dosage form development, where the physical and chemical properties of the drug are studied. It includes evaluation of solubility, pKa, partition coefficient, particle size, crystal form, flow properties, stability, and compatibility with excipients.

AI tools can predict these properties using molecular descriptors and historical databases. For example:

- Solubility prediction using ML models
- Stability prediction under temperature and humidity stress
- Polymorph identification using image recognition
- Drug-excipient compatibility prediction
- Hygroscopicity and moisture sensitivity analysis

Such predictions help scientists choose the best development pathway early and reduce experimental workload.





## 2. Formulation Optimization

Optimization is one of the most valuable applications of AI in pharmaceuticals. A formulation may contain multiple variables:

- Type and amount of binder
- Disintegrant concentration
- Lubricant level
- Polymer grade
- Granulation solvent
- Compression force
- Coating thickness

These variables influence outcomes such as:

- Tablet hardness
- Friability
- Disintegration time
- Dissolution rate
- Drug release kinetics
- Stability

Machine learning algorithms analyse past experiments and predict the best combination of variables.


**Common Algorithms Used:**

1. Artificial Neural Networks (ANN)
2. Random Forest
3. Support Vector Machine (SVM)
4. Gradient Boosting
5. Deep Learning

**Benefits:**

- Fewer laboratory trials
- Reduced development time
- Lower material wastage
- Better robustness
- Improved reproducibility

For sustained-release tablets, AI can optimize polymer ratios to achieve desired release over 12–24 hours.



### **3. AI in Manufacturing and Process Analytical Technology (PAT)**

Modern pharmaceutical manufacturing is moving from batch processes to continuous and smart manufacturing. AI plays a key role in this transformation.

PAT systems collect real-time data using sensors such as:

- NIR spectroscopy
- Raman spectroscopy
- Temperature sensors
- Pressure sensors
- Moisture analysers
- Vision cameras

AI analyses this data instantly to control the process.

#### **Applications:**

- Predict granule moisture content
- Detect blending non-uniformity
- Optimize drying endpoint
- Predict tablet weight variation
- Identify equipment failure before breakdown
- Maintain process consistency

#### **Predictive Maintenance:**

AI detects abnormal vibration, heat, or motor load patterns and warns engineers before equipment failure.

#### **Continuous Manufacturing:**

AI can automatically adjust feeder speed, compression force, or drying temperature to maintain product quality.

### **4. Quality Control and Quality Assurance**

Quality control ensures that pharmaceutical products meet required specifications. AI enhances QC by making inspection faster, more accurate, and less dependent on manual effort.

### **Applications in QC:**

- Visual inspection of tablets/capsules
- Detection of cracks, chipping, color variation
- Fill level inspection in bottles
- Label verification
- Blister pack defect detection
- Trend analysis for hardness/friability data
- Dissolution profile prediction

### **Computer Vision:**

Cameras combined with deep learning can inspect thousands of tablets per minute.

### **Analytical Prediction:**

ML models can correlate rapid spectroscopy data with assay or dissolution values, reducing testing time.

## **5. Personalized Medicine and 3D Printing**

Patients often respond differently to the same medicine due to age, genetics, disease condition, organ function, and co-medications. AI supports personalized therapy by selecting individualized doses and dosage forms.

### **Examples:**

- Paediatric dose adjustment
- Geriatric low-dose formulations
- Oncology precision dosing
- Polypharmacy interaction management
- Personalized release profiles

### **AI + 3D Printing:**

AI can design tablets with customized geometry, dose strength, and release behavior, then produce them using pharmaceutical 3D printers.

This is highly useful in rare diseases and personalized treatment plans.

## **6. Challenges and Limitations: -**

Although AI has major potential, several barriers remain.

### **1. Data Quality**

Poor, incomplete, or inconsistent data leads to unreliable models.

### **2. Small Datasets**

Many formulation studies have limited experiments, which can reduce model accuracy.

### **3. Interpretability**

Some models behave like “black boxes,” making decisions hard to explain.

### **4. Regulatory Acceptance**

Authorities require validation, transparency, and compliance before approving AI-based systems.

### **5. Cybersecurity**

Connected manufacturing systems may be vulnerable to digital threats.

### **6. Skilled Workforce**

Pharmaceutical companies need professionals trained in both pharmaceuticals and data science.

### **7. Future Scope: -**

The future of pharmaceutical formulations will be increasingly intelligent and automated.

### **Emerging Trends:**

- Digital twins of manufacturing plants
- Autonomous formulation laboratories
- Generative AI for excipient selection
- AI-guided nanomedicine design
- Real-time release testing
- Smart packaging with sensors
- Cloud-connected production systems
- Robotics in formulation screening

AI will not replace formulation scientists, but it will significantly enhance their productivity and decision-making capability.

### **REFERENCES: -**

1. Vamathevan J, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discovery*. 2019.
2. Ekins S. The next era: deep learning in pharmaceutical research. *Pharm Res*. 2016.
3. Paul D, et al. Artificial intelligence in pharmaceuticals and drug delivery. *J Control Release*. 2023.
4. Yu LX. Pharmaceutical quality by design. *Int J Pharm*. 2008.
5. LeCun Y, et al. Deep learning. *Nature*. 2015.
6. Mayr A, et al. DeepTox. *Front Environ Sci*. 2016.
7. Ramsundar B, et al. Deep learning for life sciences. O'Reilly. 2019.
8. Chen H, et al. Rise of deep learning in drug discovery. *Drug Discov Today*. 2018.
9. Zhavoronkov A, et al. AI for drug discovery. *Mol Pharm*. 2018.
10. Jiménez-Luna J, et al. Explainable AI in drug discovery. *Nat Mach Intell*. 2020.
11. Kourou K, et al. Machine learning in medicine. *Comput Struct Biotechnol J*. 2015.
12. Basile AO, et al. AI for drug toxicity and safety. *Trends Pharmacol Sci*. 2019.
13. Wu Z, et al. MoleculeNet benchmark. *Chem Sci*. 2018.
14. Yang K, et al. Molecular representations for prediction. *J Chem Inf Model*. 2019.
15. Feinberg EN, et al. PotentialNet. *ACS Cent Sci*. 2018.
16. Ma J, et al. Deep neural nets for QSAR. *J Chem Inf Model*. 2015.
17. Fourches D, et al. Trustworthy QSAR models. *Nat Chem Biol*. 2015.
18. Mansouri K, et al. OPERA models. *J Cheminform*. 2018.
19. Cheng F, et al. AdmetSAR database. *J Chem Inf Model*. 2012.
20. Yang H, et al. admetSAR 2.0. *Bioinformatics*. 2019.
21. Madabhushi A, Lee G. AI in pathology. *Med Image Anal*. 2016.
22. Bera K, et al. AI in digital pathology. *Nat Rev Clin Oncol*. 2019.
23. Tatonetti NP, et al. Prediction of drug effects. *Sci Transl Med*. 2012.
24. Zitnik M, et al. Side effects with graph networks. *Bioinformatics*. 2018.
25. Liu R, et al. Evaluating deep learning for toxicity. *Chem Res Toxicol*. 2017.
26. Xu Y, et al. Deep learning for DILI prediction. *Chem Res Toxicol*. 2015.
27. Karim A, et al. hERG liability prediction. *Bioinformatics*. 2021.
28. Braga RC, et al. Pred-hERG tool. *Mol Inform*. 2015.
29. Alves VM, et al. Acute toxicity QSAR. *Chem Res Toxicol*. 2018.
30. Zhu H. Big data and AI modeling for toxicity. *Annu Rev Pharmacol Toxicol*. 2020.
31. Kola I, Landis J. Attrition rates in pharma. *Nat Rev Drug Discov*. 2004.

32. Andrade RJ, et al. Drug-induced liver injury. *Nat Rev Dis Primers*. 2019.
33. Chen M, et al. Predicting idiosyncratic DILI. *Expert Rev Gastroenterol Hepatol*. 2014.
34. Thakkar S, et al. DILRank. *Drug Discov Today*. 2020.
35. Goh GB, et al. Deep learning for computational chemistry. *J Comput Chem*. 2017.
36. Wenzel J, et al. Multitask DNN for ADMET. *J Chem Inf Model*. 2019.
37. Cortés-Ciriano I, et al. Kohonen maps for toxicity. *J Cheminform*. 2019.
38. Jeong J, et al. Drug-drug toxicity prediction. *Bioinformatics*. 2019.
39. Ryu JY, et al. Deep learning improves DDI prediction. *PNAS*. 2018.
40. Takarabe M, et al. Drug target prediction using adverse events. *Bioinformatics*. 2012.
41. Williams AJ, et al. PubChem for toxicology. *Nucleic Acids Res*. 2017.
42. Davis AP, et al. Comparative Toxicogenomics Database. *Nucleic Acids Res*. 2021.
43. Wang Y, et al. PubChem BioAssay database. *Nucleic Acids Res*. 2012.
44. Schyman P, et al. Acute toxicity models. *J Chem Inf Model*. 2017.
45. Zhang L, et al. ML to deep learning in ADMET. *Drug Discov Today*. 2017.
46. Raies AB, Bajic VB. In silico toxicology methods. *WIREs Comput Mol Sci*. 2016.
47. Cherkasov A, et al. QSAR modeling review. *J Med Chem*. 2014.
48. Lin Z, Chou WC. AI in toxicological sciences. *Toxicol Sci*. 2022.
49. Zhang R, et al. AI-driven toxicity prediction. *Toxics*. 2025.
50. Mostafa F, Chen M. Liver toxicity models. *Front Toxicol*. 2024.
51. Paul S, et al. AI in controlled release systems. *Int J Pharm*. 2022.
52. Sharma P, et al. AI in tablet formulation optimization. *Pharm Dev Technol*. 2021.
53. Gupta R, et al. Machine learning in dosage design. *AAPS PharmSciTech*. 2020.
54. Singh A, et al. AI in continuous manufacturing. *Eur J Pharm Sci*. 2023.
55. Kumar V, et al. AI for PAT systems. *J Pharm Innov*. 2022.
56. Mehta D, et al. Computer vision in QC. *Pharm Technol*. 2021.
57. Rao N, et al. Smart factories in pharma. *Future Pharm*. 2024.
58. Patel H, et al. AI and 3D printed medicines. *Drug Dev Ind Pharm*. 2023.
59. Verma S, et al. Personalized formulations using AI. *Int J Pharmaceutics*. 2024.